Genetic mutations in *pfcr* and *pfmdr1* at the time of artemisinin combination therapy introduction in South Pacific islands of Vanuatu and Solomon Islands

Karryn J Gresty¹,², Karen-Ann Gray¹,², Albino Bobogare³, George Taleo⁴, Jeffrey Hii⁵, Lyndes Wini³, Qin Cheng¹,² and Norman C Waters¹,⁶*

**Abstract**

**Background:** Chloroquine (CQ), alone or in combination with sulphadoxine-pyrimethamine, was widely used for the treatment of *Plasmodium falciparum* and *Plasmodium vivax* for several decades in both Vanuatu and Solomon Islands prior to the introduction of artemether-lumefantrine (AL) in 2008. However, the effect of chloroquine selection on parasite population, which may affect the efficacy of lumefantrine or other partner drugs of artemisinin, has not been well assessed. This study aims to provide baseline data on molecular markers (*pfcr* and *pfmdr1*), along with the origins of *pfcr*, prior to the introduction of AL.

**Methods:** Blood spots were obtained from epidemiological surveys conducted on Tanna Island, Tafea Province, Vanuatu and Temotu Province, Solomon Islands in 2008. Additional samples from Malaita Province, Solomon Islands were collected as part of an artemether-lumefantrine efficacy study in 2008. *Plasmodium falciparum pfcr* and *pfmdr1* genes were examined for polymorphisms. Microsatellite markers flanking *pfcr* were also examined to ascertain origins of CQ resistance.

**Results:** *Pfcr* analysis revealed 100% of parasites from Tafea Province, Vanuatu and Malaita Province, Solomon Islands and 98% of parasites from Temotu Province, Solomon Islands carried the K76T polymorphism that confers CQ resistance. Comparison of *pfcr* allelic patterns and microsatellite markers flanking *pfcr* revealed six haplotypes with more than 70% of isolates possessing haplotypes very similar to those observed in Papua New Guinea. The dominant (98.5%) *pfmdr1* allele across all island groups was YYCN.

**Conclusions:** Prior to the introduction of AL in the Solomon Islands and Vanuatu, *P. falciparum* isolates possessed point mutations known to confer CQ resistance and possibly associated with a decreased susceptibility to quinine and halofantrine, but an increased susceptibility to artemisinin and lumefantrine. Overall, *pfcr* allelic types and the flanking microsatellite markers exhibited similarities to those of Papua New Guinea, suggesting these parasites share a common ancestry. The current use of AL for both *P. falciparum* and *P. vivax* infections will enable changes in these markers, in the absence of CQ pressure, to be monitored.

**Keywords:** *Plasmodium falciparum*, Chloroquine, *pfcr*, Microsatellite markers, Surveillance, Molecular markers, Vanuatu, Solomon Islands

* Correspondence: norman.c.waters2.mil@mail.mil

¹Australian Army Malaria Institute, Enoggera, Brisbane, Queensland, Australia
²Walter Reed Army Institute of Research, Malaria Vaccine Branch, Military Malaria Research Program, Silver Spring, Maryland, USA

Full list of author information is available at the end of the article.

© 2014 Gresty et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Chloroquine-resistant (CQR) *Plasmodium falciparum* parasites arose in the late 1960s and have since spread throughout most malaria-endemic regions rendering chloroquine (CQ) ineffective in many areas. The spread of CQ resistance has been attributed to the resurgence of malaria morbidity and mortality during the 1990s [1,2]. In 2001, the World Health Organization (WHO) recommended the use of artemisinin-based combination therapy (ACT) for treatment of uncomplicated *P. falciparum* malaria [3]. Following this recommendation, the South Pacific countries of Vanuatu and Solomon Islands introduced ACT in 2008 [4].

CQ resistance in *P. falciparum* has been reported to associate with mutations in the parasite CQ resistance transporter gene (*pfcr*) located on chromosome 7. Molecular studies demonstrated that resistance to CQ results from a series of mutations in *pfcr*, of particular importance is the mutation causing a change from lysine (K) to threonine (T) at amino acid 76 [5,6]. The K76T and 11 other amino acids have been used as molecular markers for studying the evolution of CQ resistance. Various combinations of *pfcr* mutations have been identified in different geographical locations and have been linked to past drug exposure [7].

Worldwide, there has been at least five major independent geographical origins of CQR *pfcr* alleles. Initially four lineages were identified; one each from Indochina/Africa (CVIET) and Melanesia (SVMNT), and two from South America (SVMNT) [8-10]; a fifth lineage was later identified from the Philippines (C/SVMNT) [11,12]. Furthermore, SVMNT has also been linked with historical amodiaquine use [7]. The origins of various *pfcr* alleles have been mapped using microsatellite markers flanking *pfcr* [9,10,12]. Microsatellites (MS) are short, simple, sequence repeats, and are prolific in the *P. falciparum* genome. When drug pressure exists in a parasite population, mutations that are advantageous to the parasite, for example those leading to drug resistance, are selected and propagated throughout the population. The MS markers that flank these resistance genes can also be propagated throughout the population via a form of genetic ‘hitchhiking’ [9]. This leads to a reduction in the variation of allele frequency of the MS markers closest to the locus under selection [9].

*Pfcr* mutations can also affect parasite susceptibilities to other anti-malarial drugs. For example, wild type *pfcr* alleles confer a reduced susceptibility to lumefantrine, while mutant alleles can result in increased sensitivity to lumefantrine [13]. Transfection experiments have demonstrated the K76T mutation as the main determinant of *pfcr*-dependent lumefantrine susceptibility [13]. Similarly, susceptibility levels of amodiaquine have been found to vary depending on the geographic origin of the mutant *pfcr* alleles [7].

The multidrug resistance gene (*pfmdr1*) coding for P-glycoprotein homologue-1 (pgh-1) located on chromosome 5 [14-16] was also implicated in CQ resistance. Mutations in *pfmdr1* result in changes at amino acids 86, 184, 1034, 1042, and 1246, and these changes have been associated with CQR in laboratory clones [14] although their associations with CQR were strain specific [15]. These polymorphisms in the *pfmdr1* gene were also shown to affect parasite susceptibilities to structurally diverse antimalarial compounds, for example quinine, halofantrine, mefloquine, CQ, and artemisinin in vitro [15,17]. Additionally, an increase in copy number of the *pfmdr1* gene was reported to play a role in reduced parasite susceptibility to artemisinin derivatives as well as mefloquine, halofantrine and quinine [18-20].

Both *P. falciparum* and *Plasmodium vivax* are endemic to the Solomon Islands and Vanuatu (except for the islands of Anéityum and Futuna which are malaria-free). CQ was used as first-line therapy, alone or with sulphadoxine-pirimethamine (SP), for both *P. falciparum* and *P. vivax* infections until 2008. Reduced susceptibility of *P. falciparum* parasites to CQ was first described in the Solomon Islands in 1980, initially occurring in Western, Central, Guadalcanal, and Malaita Provinces, extending countrywide in later years [21,22]. In 2001, as the 28-day CQ treatment failure rate reached 67% [22] Solomon Islands replaced CQ with CQ plus SP as first-line therapy for uncomplicated falciparum malaria. In Vanuatu, resistance to CQ was first reported in 1987, following this the Vanuatu Ministry of Health introduced a new treatment regime in 1994, changing the treatment of uncomplicated *P. falciparum* infection from CQ monotherapy to a combination therapy of CQ and SP, while CQ remained the treatment for *P. vivax* infections [22]. A therapeutic efficacy study conducted in 2001 revealed a 16% treatment failure rate for CQ plus SP [22]. Despite these clinical reports, there is limited molecular data published on the prevalence of CQR malaria in Vanuatu and the Solomon Islands and their origins.

Vanuatu and the Solomon Islands are presently intensifying malaria control countrywide and progressing towards malaria elimination in targeted provinces. The success of eradicating malaria is dependent on many factors, not least of which is overcoming the challenge of drug resistance; malaria epidemiology is an integral component of any elimination strategy. Knowledge of baseline drug-resistant genotypes and their changes over time in parasite populations is critical to monitoring emergence of drug resistance and informing treatment policy. In 2008 artemether-lumefantrine (AL) was introduced to treat uncomplicated *P. falciparum* infections in both Vanuatu and the Solomon Islands. ACT is currently the first-line treatment for vivax malaria in both countries [4]. It is important to document parasite molecular drug resistance...
profiles at the time of AL introduction and use this baseline information for detection of future changes under AL pressure. Furthermore, the baseline information may also inform parasite susceptibility to companion drugs of ACT.

In this study, the occurrence and prevalence of mutations in pfcrt and pfmdr1 was examined. Samples used in this study were collected from villages across several isolated groups of islands from Vanuatu and the Solomon Islands in 2008. The origins of CQ resistance was also investigated by analysing the MS loci surrounding the pfcrt gene.

Methods
Study areas and sample collection
Samples used in this paper were collected in three separate studies. Two sets were obtained from epidemiological surveys conducted (2008) during the wet seasons in:

1. Tafea Province, Vanuatu. This was a school-based, mass blood survey of children (2-12 years) where 73% of all children both febrile and non-febrile were assessed for malaria infection.
2. Temotu Province, Solomon Islands. This was a village-based mass blood survey encompassing all ages where 50.2% of the provincial population both febrile and non-febrile were assessed for malaria infection.

The geographic locations and information regarding the demographics of the populations surveyed and consent process for both these surveys have been published previously [23].

The third set of samples was from an AL (Coartem™, Novartis) therapeutic efficacy study conducted (June to October 2008) in the Province of Malaita, Solomon Islands (Wini et al., unpublished). Febrile patients (2-68 years) attending Auki town clinic and Kili’Ufi General Hospital were recruited by the Ministry of Health staff, Solomon Islands in collaboration with WHO. Malaita Province lies approximately 9°S 161°E and is the second largest and most densely populated Province of the Solomon Islands. In these areas malaria transmission is perennial with peaks between November and August.

Across all study sites blood samples were collected by finger prick. A blood spot (20-30 μL) was air-dried onto filter paper (Whatman No 3), sealed in individual plastic bags containing desiccant and stored at room temperature until further processing.

Parasite DNA extraction and PCR speciation
Extraction of genomic DNA from blood on filter paper and PCR to determine Plasmodium species has been described previously [23].

Parasite speciation by multiplex PCR
Plasmodium speciation was performed using species-specific primers in a multiplex PCR as previously described [24] to identify P. falciparum, P. vivax, Plasmodium ovale or Plasmodium malariae infections in blood samples.

Mutations in pfcrt
The extracted DNA was used as the template for PCR amplification of pfcrt. Initially PCR/RFLP analysis [25] was used to determine isolates exhibiting the K76T substitution indicative of CQ resistance. Random subsets of these samples (17 from Tafea, 50 from Temotu and 31 from Malaita Provinces) were selected for further analysis of additional codons. DNA fragments covering 12 known mutations in pfcrt were amplified by nested PCR as described previously [26]. For Tafea and Temotu Provinces, in addition to codon 76, 11 other codons were examined (72, 74, 75, 97, 144, 160, 220, 271, 326, 356, and 371), only four additional codons (72, 74, 75, and 97) were determined for samples from Malaita Province.

Mutations in Pfmdr1
Random subsets of samples (17 from Tafea, 37 from Temotu and 31 from Malaita Provinces) were selected for sequence analysis. The extracted DNA was used as the template for PCR amplification of DNA fragments covering five amino acid codons in pfmdr1 (86, 184, 1034, 1042, and 1246) known to affect drug resistance levels as described previously [27].

DNA sequencing
All PCR amplifications generating a single product were incubated with ExoSAP-IT® (USB, Cleveland, OH, USA) to remove excess primers and nucleotides according to the manufacturer’s protocol and then sequenced. In cases where PCR products contained multiple bands, a single band of expected size was excised and purified using a NucleoSpin® extraction kit (Macherey-Nagel) and then sequenced. Sequencing was performed using a Big Dye Terminator kit (v.3.1) on an automated DNA sequencer, ABI 3100 system, at the QIMR Berghofer Medical Research Institute Scientific Services Analytical Facility.

Plasmodium falciparum microsatellite genotyping
For selected samples five MS markers flanking the pfcrt gene, B5M77 (-20 kb), 2E10 (-5 kb), PE12A (+6 kb), 2H4 (+22 kb), and PE14F (+106 kb), were amplified and analysed as described previously [9]. An additional six P. falciparum laboratory isolates (AN001, AN018, Dd2, C2B, PH1, and 7G8) obtained from diverse geographical regions were analysed as reference strains [12]. MS sizes in samples were compared to these reference strains and calibrated accordingly.
Results

Prevalence of mutations in pfcr
t
Sequences of pfcr were examined and the prevalence of mutations determined for the three island groups. Amino acid substitutions were identified at codons 72, 76, 220, 326, and 356 whereas wild type amino acids were observed at codons 97, 144 and 160. Initial PCR/RFLP analysis revealed 100% of parasites from Tafea Province, Vanuatu and Malaita Province, Solomon Islands and 98% of parasites from Temotu Province, Solomon Islands carried the K76T substitution indicative of CQR (Table 1). Only one sample from the village of Neo on Santa Cruz Island, Temotu Province exhibited the wild type lysine (K) at codon 76 as well as cysteine (C) at codon 72, however this sample had the A220S substitution (Table 2). All three island groups possessed pfcr C72S and K76T substitutions at 94 and 98% or greater, respectively. Likewise, polymorphisms A220S, N326D/S and 356 L/T were 91% or greater for Tafea and Temotu Provinces (these codons were not examined for Malaita Province).

All other codons examined indicated predominance for wild type amino acids M74, N75, H97, A144, L160, Q271, and R371 (Table 1).

Pfcrt allelic types

Sequence analysis of pfcrt at codons 72, 74, 75, 76, and 97 were completed for all samples investigated (17 from Tafea, 50 from Temotu and 31 from Malaita Provinces) and results revealed that 96/98 (98%) to be allelic type MN. One other mutant allelic type CIETH was identified in a sample from Vanuatu while a wild type allele CMNKH was identified in one sample from Temotu Province, Solomon Islands.

In conjunction with these five codons, additional PfCRT amino acids 144, 160, 220, 271, 326, 356, and 371 were examined in samples from Tafea Province, Vanuatu and Temotu Province, Solomon Islands. Amino acids were determined at all 12 codons investigated for 48 isolates from Tafea Province, Vanuatu and Temotu Province, Solomon Islands, with remaining isolates having incomplete amino acid identification at one or more codons. Of the 51 completed sequences a predominant allele, SMNTHALSDLR, was identified in 38 isolates (74.5%), with the remainder being predominantly polymorphic at codons 271, 326 and 356. This predominant allele was found in 83% (5/6) and 73% (33/45) of samples from Tafea Province, Vanuatu and Temotu Province, Solomon Islands, respectively. One sample from Port Resolution on Tanna Island, Tafea Province possessed allele CIETHALSE*TR (unidentified amino acids are represented by asterisk) similar to the dominant allele in samples originating in Thailand. In Tafea Province, Vanuatu, 33% (3/9) of samples possessed the Q271E mutation most commonly seen in Thailand. Interestingly, this mutation was not detected in Temotu Province, Solomon Islands despite twice the number of samples being examined. Furthermore, one CQR isolate (SMNTH**A**TR) from the village of Ngamubulo, situated on the Reef Islands, Temotu Province, Solomon Islands did not exhibit the A220S polymorphism generally associated with CQR alleles. Observed allelic types and their prevalence in the different island groups are summarized in Table 2.

Microsatellite haplotypes

Throughout the island provinces, genotyping of five MS markers flanking pfcrt revealed six haplotypes (based on similarity of 4/5 markers), H1-H6. The prevalence of each haplotype is different between the island groups (Table 2 and Table 3).

In Temotu Province, Solomon Islands, 34 of the 50 samples were successfully typed at all five loci and resulted in three haplotypes, of these 76.5% (26/34) and 20.6% (7/34) were H3 and H4, respectively, representing 97.1% of the parasite population (Table 3). These haplotypes have been reported in PNG (AN018 and AN001 groups). Interestingly, one sample from the village of Neo on Santa Cruz Island possessing a single A220S polymorphism, exhibited the Southeast Asian pfcrt allelic type and also had a MS pattern matching that of the Thailand C2B group at all three downstream MS loci.

In Malaita Province, Solomon Islands, 28 of the 31 isolates were successfully typed at all five loci and revealed four MS haplotypes (based on similarity of 4/5 MS markers). Of these 71.4% (20/28) and 14.3% (4/28) were H3 and H4, respectively, representing 85.7% of parasite population (Table 3). Three samples were classified as H1, H2, and H5.

Table 1 Prevalence (%) of amino acid substitutions in PFCRT in Plasmodium falciparum samples collected from Tafea Province, Vanuatu and Temotu and Malaita Provinces, Solomon Islands

| Country         | Province | n  | % substitutions at amino acid positions in PFCRT |
|-----------------|----------|----|-----------------------------------------------|
|                 |          |    | 72  | 74  | 75  | 76  | 97  | 144 | 160 | 220 | 271 | 326 | 356 | 371 |
| Vanuatu         | Tafea    | 17 | 94  | 6   | 6   | 100 | 0   | 0   | 100 | 43  | 100 | 94  | 47  |
| Solomon Islands | Temotu   | 50 | 98  | 0   | 0   | 98  | 0   | 0   | 98  | 0   | 91  | 98  | 22  |
|                 | Malaita  | 31 | 100 | 0   | 0   | 100 | 0   | *   | *   | *   | *   | *   | *   |

PFCRT = Plasmodium falciparum chloroquine resistance transporter.

* = not determined.
Table 2 Pfmdr1 and pfcrt genotypes and MS markers flanking pfcrt in Plasmodium falciparum samples collected from Tafea Province, Vanuatu and Temotu and Malaita Provinces, Solomon Islands compared to reference samples

| Origin (no. isolates) | n | H | %  | MS* marker size (bp) | AA positions in Pfcr** | MS* marker size (bp) | AA positions in Pfmdr1** |
|-----------------------|---|---|----|----------------------|------------------------|----------------------|-------------------------|
|                       |   |   |    | B5M77 2E10            |                        | PE12A 2H4 PE14F      |                         |
| Vanuatu Tafea (n = 17)| 5 | 1 | 29.4 | 147 174               | SMNHALSEDLR 328 192 139 | YYCNND              |
|                       | 4 | 1 | 29.4 | 147 174               | SMNHALSEDLI 328 184 142 | YYCNND              |
|                       | 1 | 1 | 5.9  | 147 174               | SMNHALSE**R * * *      | YYCNND              |
|                       | 5 | 1 | 29.4 | * *                   | SMNHALSE**TI * * *     | YYCNND              |
|                       | 1 | 1 | 5.9  | * *                   | SMNHALSE**TR * * *     | YYCNND              |
|                       | 1 | 1 | 5.9  | * *                   | SMNHALSE**STR * * *    | YYCNND              |
|                       | 1 | 1 | 5.9  | * *                   | CIETHALSE**TR * * *    | YYCNND              |
| Solomon Islands Temotu (n = 50) | 23 | 3 | 64.7 | 149 174               | SMNHALSEDLR 328 192 139 | YYCNND              |
|                       | 4 | 1 | 29.4 | 149 174               | SMNHALSEDLI 328 184 134 | YYCNND              |
|                       | 4 | 1 | 29.4 | 149 174               | SMNHALSEDLI 328 184 136 | YYCNND              |
|                       | 1 | 1 | 2.9  | 149 174               | SMNHALSE**R * * *      | YYYND               |
|                       | 1 | 1 | 2.9  | 149 174               | SMNHALSE**TR * * *     | **CNND              |
|                       | 1 | 1 | 2.9  | 149 174               | SMNHALSE**TR * * *     | **CNND              |
|                       | 1 | 1 | 5.9  | 149 174               | SMNHALSE**STI * * *    | **CNND              |
|                       | 1 | 1 | 5.9  | 149 174               | SMNHALSE**STI * * *    | **CNND              |
|                       | 1 | 1 | 5.9  | 149 174               | SMNHALSE**STI * * *    | **CNND              |
|                       | 1 | 1 | 5.9  | 149 174               | SMNHALSE**STI * * *    | **CNND              |
| Solomon Islands Malaita (n = 31) | 9 | 3 | 29.4 | 149 174               | SMNHALSEDLR 328 192 139 | YYCNND              |
|                       | 11 | 3 | 35.5 | 149 174               | SMNHALSEDLI 328 192 139 | YYCNND              |
|                       | 4 | 4 | 12.9 | 149 174               | SMNHALSE**R 328 184 145 | YYCNND              |
|                       | 1 | 1 | 3.2  | 149 154               | SMNHALSE**STI 328 192 142 | YYCNND              |
|                       | 3 | 1 | 9.7  | 147 174               | SMNHALSE**STI 328 184 142 | YYCNND              |
|                       | 3 | 1 | 9.7  | * *                   | SMNHALSE**STI * * *    | YYCNND              |
| World reference Samples | | |    | | |                      |                         |
| Brazil 7G8            | 151 | 190 | SMNHALSEDLR 314 194 142 |                      |                         |
| Philippines PH1       | 149 | 182 | CMMNHITLEYAGDLR 314 228 136 |                      |                         |
| Thailand Dd2          | 149 | 170 | CIEHALSE**STI 314 204 145 |                      |                         |
| Thailand C2B          | 149 | 170 | CIEHALSE**STI 314 184 148 |                      |                         |
| Solomon Island N18    | 149 | 174 | SMNHALSEDLR 328 184 142 |                      |                         |
| PNG AN001             | 149 | 174 | SMNHALSEDLR 328 184 142 |                      |                         |
| PNG AN018             | 149 | 174 | SMNHALSEDLR 328 184 139 |                      |                         |

Note: Boldface amino acids represent the mutated state of that codon.
* MS microsatellite upstream of pfcrtB5M77 (~20 kb) and 2E10 (~5 kb).
** Amino acid (AA) positions in pfcrt are 72, 74, 75, 76, 97, 144, 160, 220, 271, 326, 356, 371.
* MS microsatellite downstream of pfcrt: PE12A (+6 kb), 2H4 (+22 kb) and PE14F (+106 kb).
** or *** indicates 2 or 3 AA positions were not determined.
possessing a variation at an upstream locus compared to H3 and H4. One sample was determined H6, also having a variation at an upstream locus.

In Tanna Island, Vanuatu, eight of 17 isolates were successfully typed at all five loci resulting in two patterns (based on similarity of 4/5 MS markers). Of these 75% (6/8) were determined as H1 (Table 3) showing close identity to those observed for the Solomon N70 group [12]. The two remaining samples, from the village of Fetukai, had unique MS sizes at three loci, while locus PE14F was observed to be identical to samples from the Thailand C2B group. These two samples were classified as H2. Interestingly, despite having the SMNTHAL in PfCRT, they also possessed a change in amino acid from glutamine (Q) to glutamic acid (E) at codon 271, a characteristic common to both groups of samples originating from Thailand (Dd2 and C2B).

Prevalence of mutations in pfmdr1
Sequences of pfmdr1 were analysed and the prevalence of mutations in the three island groups determined (Table 4). Amino acid substitutions were identified at codons 86, 184 and 1034 while only wild type codons were observed at 1042 and 1246. Polymorphisms N86Y and S1034C were present in 100% of samples from both countries, while one sample from Vanuatu possessed an additional mutation Y184F. The dominant pfmdr1 allele across all island groups was YYCND. The observed allelic types in the different island groups are summarized in Table 2.

Discussion
CQ has been used widely in the South Pacific for many years and has applied a strong selection pressure on parasite populations, which may affect the efficacy of ACT. Vanuatu and the Solomon Islands are among the few countries where ACT is currently used for treatment of both P. falciparum and P. vivax malaria. Understanding the parasite drug resistance profile at the time of ACT introduction allows for detection of changes in future parasite populations. It will also enable a better understanding of potential changes in drug resistance profiles for both species in the absence of CQ drug pressure. In this paper, the baseline data on pfcr and pfmdr1 was investigated at the time of AL introduction.

Overall results of this study indicated a dominance of the SmNT allele across all island groups. Amino acid analysis indicated 100% of samples examined from Tafea Province, Vanuatu and Malaita Province, Solomon Islands, and 98.8% of samples from Temotu Province, Solomon Islands possessed the K76T polymorphism indicative of CQ resistance, and possibly impaired quinine and halofantrine susceptibility. This also demonstrates that the CQR pfcr allele is at fixation in these three island group populations of Vanuatu and Solomon Islands. The high prevalence of CQR parasites in these two countries is not surprising given CQ monotherapy was the primary chemotherapeutic drug used to treat uncomplicated P. falciparum malaria for several decades, and until relatively recently, was also the treatment of choice for P. vivax infections. Although CQ has not been used in Vanuatu and the Solomon Islands as a monotherapy since 1994 and 1991, respectively, it was still used in combination therapy for treatment of P. vivax infections. This continued CQ pressure provides a reasonable explanation for the prevalence of the 76T mutation in these parasite populations. Interestingly, published in vivo and in vitro studies suggest the effectiveness of lumezantrine is enhanced in P. falciparum parasites carrying the pfcr K76T mutation [13]. This suggests that lumezantrine is an ideal ACT partner drug to use in Vanuatu and the Solomon Islands as both these regions exhibit high levels of CQ resistance.

All samples exhibiting the K76T polymorphism also possessed additional mutations occurring in at least one of the following codons 220, 326, 356, and 371. While SMNTHALSQDLR was predominant on all three island groups, variation in pfcr genotypes exists not only between these two countries but also within island groups. In Temotu Province, one of 50 samples analysed retained a wild type K76 in conjunction with a single A220S polymorphism (genotype CMNKHALSQNIR). Although the A220S polymorphism in pfcr has been shown to increase the level of CQ resistance when co-existing with K76T, it is unlikely that a single A220S polymorphism is sufficient to confer CQR [28]. In contrast, another isolate from the village of Ngamubulo situated on the Reef Islands did not exhibit the A220S substitution generally associated with

Table 3 Prevalence of MS haplotypes between different island groups

| Country     | Province | H1 | H2 | H3 | H4 | H5 | H6 |
|-------------|----------|----|----|----|----|----|----|
| Solomon     | Temotu   | 0.0| 0.0| 76.5|20.6| 2.9| 0.0|
|             | Malaita  | 7.1| 0.0| 71.4|14.3| 0.0| 7.1|
| Vanuatu     | Tafea    | 75.0|25.0| 0.0| 0.0| 0.0| 0.0|

Table 4 Prevalence (%) of amino acid substitutions in PfMDR1 in Plasmodium falciparum samples collected from Tafea Province, Vanuatu and Temotu and Malaita Provinces, Solomon Islands

| Country       | Province | n   | 86  | 184 | 1034 | 1042 | 1246 |
|---------------|----------|-----|-----|-----|------|------|------|
| Vanuatu       | Tafea    | 17  | 100 | 6   | 100  | 0    | 0    |
| Solomon Islands | Temotu | 37  | 100 | 0   | 100  | 0    | 0    |
|                | Malaita  | 31  | 100 | 0   | 100  | 0    | 0    |

PfMDR1 = Plasmodium falciparum multidrug resistance protein 1.
CQR alleles having a genotype of SMNTH**A**TR. The occurrence of the A220 in combination with the K76T mutation, although not common, has been previously documented in isolates from the Philippines, as well as India and China [12,29,30]. Q is found at codon 271 in all samples, including reference samples, except those originating in Thailand, which predominantly contain an E at this position. Interestingly, 43% of samples from Tafea Province, Vanuatu contained the Q271E substitution. At this point the drug pressure that selects for this polymorphism is not understood; however, it may be indicative of changes in drug sensitivity profiles and/or the subsequent sweep of drug resistant alleles throughout the region, hence this codon may be a key amino acid for future surveillance studies.

Overall, results indicated that 74.5% (38/51) of samples collected from Tafea Province, Vanuatu and Temotu Province, Solomon Islands, for which all 12 pfcrt codons could be determined, had a pfcrt allelic type identical to those from Papua New Guinea (PNG). This may indicate a gene flow of parasite alleles between these island groups and suggests that malaria drug resistance in these provinces is similar to PNG. At this time it is unclear if clinical drug resistance differences exist between Tafea Province, Vanuatu and Temotu Province, Solomon Islands, however pfcrt analysis of P. falciparum samples collected from these locations predict similar drug susceptibilities. Furthermore, the SMNTH allelic type of pfcrt in these island groups suggests a past parasite exposure to amodiaquine (AQ) [7] although no evidence of AQ use in either Vanuatu or the Solomon Islands is evident. AQ was however introduced in PNG in 1966 and given its close geographical proximity, the likelihood of drug resistance genotypes becoming established in the neighbouring countries of Solomon Islands and Vanuatu seems predictable.

Analysis of five MS markers flanking pfcrt was undertaken to determine whether parasites harbouring mutations that conferred CQR evolved locally or originated via gene flow from other countries. Overall, 70 of 98 samples from three island groups were typed revealing six MS haplotypes. There were difficulties in obtaining MS data for many of the samples analysed, particularly from Tanna Island and Temotu Province; this was possibly due to low levels of parasitaemia in these samples as these were obtained from cross-sectional surveys of villagers most of whom were asymptomatic and had low parasitaemia at time of survey. Interestingly, also in Tafea and Temotu Provinces there was a high incidence of asymptomatic infections. In Tafea Province only 28% of children that were slide positive for malaria were febrile while in Temotu Province only 14% of all ages tested that were slide positive for malaria were febrile [31]. This suggests in these regions that a high proportion of people infected with malaria were asymptomatic. In comparison 63% of samples collected from Malaita Province were from febrile patients attending the clinic or hospital. This implies that only sampling from symptomatic individuals (ie. those attending clinics or hospitals) has the potential to miss many positive malaria cases and this may lead to undetected genotypes circulating within populations.

Interestingly, the distribution and prevalence of the six haplotypes were different between the island groups. H3 and H4 were predominant haplotypes in both Temotu and Malaita Provinces, Solomon Islands. Both these haplotypes were also dominant types in PNG [10,12]. The MS and the pfcrt typing results strongly indicate that CQR parasites in two different provinces of Solomon Islands share the same origin as those from PNG and may have resulted from a spread via PNG. Minor haplotypes were also observed in these two island groups, H5 was present in Temotu while H1 and H6 were in Malaita Province. H5 has a distinct MS pattern upstream to pfcrt and has a wild type pfcrt representing a minor CQ-sensitive parasite population. The minor types H1 and H6, have small variations to H3 and H4, and may have resulted from genetic drift.

In Tafea Province, Vanuatu, H1 appears to be the dominant haplotype albeit the sample number is relatively small. Although there is variation, it is closely related to H4, which has been reported in samples from Guadalcanal, Solomon Islands previously [12]. Therefore, parasites in this province may have spread from Solomon Islands or PNG. The haplotype H2 (n = 2) observed in this location may have been generated from a recombination between Southeast Asian and PNG parasites. The Q271E polymorphism detected in these two parasites, which is common to Southeast Asian CQR parasites, and the presence of Southeast Asian CQR pfcrt allele in the province support this hypothesis.

Interactions between pfcrt and pfmdr1 mutations and their combined effect on drug resistance are not clear. Like pfcrt, direct evidence has demonstrated that point mutations in pfmdr1 can confer resistance to CQ, mefloquine, quinine, and halofantrine [15]. It has been suggested that the response of CQR falciparum parasites to CQ is associated not only with the pfcrt genotype but also the pfmdr1 mutations with which they are coupled [7]. In this study the dominant (98.5%) pfmdr1 allele across all island groups was YYCND, only one isolate from Vanuatu possessed a YYND allele. Studies have suggested that the Y184F mutation is associated with low-level resistance to AL [32] but as yet there has been no consensus for the role it plays in CQ resistance. The change in amino acid from asparagine to tyrosine N86Y has been associated with CQ resistance in some investigations [33-36] but not others [37-40]; this polymorphism has also been implicated in playing a modulating role in reducing the susceptibility of parasites to amodiaquine.
a 4-aminoquinoline drug structurally related to CQ. A clinical trial in Zanzibar, in which pfcr K76T and pfmdr1 N86Y frequencies were determined before AL administration and then again in all recurrent parasites during a follow-up period of 42 days, showed a significant increase in the occurrence of pfmdr1 N86, suggesting N86 as a potential marker of lumefantrine resistance in vivo [45]. Thus, future surveillance studies in Vanuatu and the Solomon Islands, post implementation of AL, will be of interest to see if there are similar changes in the frequency of pfmdr1 mutations.

Conclusions
This study provides a clear indication of widespread CQ resistance between the Solomon Islands and Vanuatu at the time of AL introduction. Overall the pfcr genotypes and the MS markers flanking them in samples from Tafea Province, Vanuatu, and Temotu and Malaita Provinces, Solomon Islands exhibited similarities to those of PNG suggesting that malaria drug resistance profiles are also similar between these countries. The recent introduction and use of AL throughout this region as first-line treatment for both Plasmodium falciparum and P. vivax infections, warrants continued surveillance not only to monitor baseline but also to observe relative changes in the pfcr allele in the absence of CQ pressure.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
KIG and KG performed experiments determining parasite species and genotypes; KIG and QC carried out data analysis; AB and GT contributed to the baseline survey; JH and LW contributed to the therapeutic efficacy studies, KIG and QC wrote the manuscript; KIG, NW, and QC conceived and designed the study. All authors read and approve the final manuscript.

Acknowledgements
We thank the Ministries of Health Solomon Islands and Vanuatu for support and approval to conduct these studies. We thank the people of the Solomon Islands and Vanuatu for their hospitality and willingness to participate in the malaria survey. We are grateful to Dr Bridget Appleyard and Dr Dorina Bustos for facilitating the therapeutic efficacy studies and standardizing the filter paper preparation in Vanuatu. Funding for the malaria survey was provided by AusAID through Pacific Malaria Initiative Supporting Centre (PaMISC), University of Queensland. Genotyping analysis and drug resistance profiling was financially supported by Department of Defense, Global Emerging Infections Surveillance Program (DoD-GEIS), USA.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of the Australian Defence Force Joint Health Command or the US Department of Defense.

Author details
1Australian Army Malaria Institute, Enoggera, Brisbane, Queensland, Australia. 2QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 3Malaria and Vector Borne Diseases Control Program, Ministry of Health, Honiara, Solomon Islands. 4Vector Borne Disease Control Program, Ministry of Health, Port Vila, Vanuatu. 5School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Townsville, Queensland, Australia. 6Walter Reed Army Institute of Research, Malaria Vaccine Branch, Military Malaria Research Program, Silver Spring, Maryland, USA.
derivatives in Plasmodium falciparum. Antimicrob Agents Chemother 2010, 54:2455–2464.

21. Bowden DK, Bastien P, Douglas FP, Muir JW, Tambiasi E: Chloroquine-resistant Plasmodium falciparum malaria in Vanuatu. Med J Aust 1982, 2:561–562.

22. WHO: Review of the malaria drug efficacy situation in 10 countries of the WHO Western Pacific Region 1987-2003. Geneva: World Health Organization, 2005.

23. The Pacific Malaria Initiative Study Group: Malaria on isolated Melanesian islands prior to the initiation of malaria elimination activities. Malar J 2010, 9:218.

24. Padley D, Moody AH, Chiidini PL, Saldanha J: Use of a rapid, single-round, multiplex PCR to detect malarial parasites and identify the species present. Ann Trop Med Parasitol 2003, 97:131–137.

25. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diouf Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D: A molecular marker for chloroquine-resistant falciparum malaria. Nat Engl J Med 2001, 344:257–263.

26. Chen N, Russell B, Staley J, Kotecka B, Nasveld P, Cheng Q: Sequence polymorphisms in pfcr are strongly associated with chloroquine resistance in Plasmodium falciparum. J Infect Dis 2001, 183:1543–1545.

27. Chen N, Russell B, Fowler E, Peters J, Cheng Q: Levels of chloroquine resistance in Plasmodium falciparum are determined by loci other than pfcr and pfmdr1. J Infect Dis 2002, 185:405–407.

28. Summers RL, Dave A, Dolsta TJ, Bellanca S, Nash MN, Richards SN, Goh V, Schenk RL, Stein WJ, Kih K, Sanchez CP, Lanzer M, Martin RE: Diverse mutational pathways converge on a susceptible chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Proc Natl Acad Sci U S A 2014, 111:E1759–E1767.

29. Mittra P, Vinyak S, Chandawat H, Das MK, Singh N, Biswas S, Dev V, Kumar A, Ansari MA, Sharma YD: Progressive increase in point mutations associated with chloroquine resistance in Plasmodium falciparum isolates from India. J Infect Dis 2006, 193:1304–1312.

30. Yang Z, Zhang Z, Sun X, Wei C, Li L, Zhang X, Zhong D, Yan G: Molecular analysis of chloroquine resistance in Plasmodium falciparum in Yunnan Province, China. Trop Med Int Health 2007, 12:1051–1056.

31. Harris I, Sharrock WW, Bain LM, Gray KA, Bobogare A, Boaz L, Lilley K, Krause D, Vallety A, Johnson ML, Gatton ML, Shanks GD, Cheng Q: A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province. Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J 2010, 9:254.

32. Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martinsson A, Bjorkman A, Krishna S, Gil JP: The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health 2007, 12:736–742.

33. Babiker HA, Pringle SJ, Ibel-Muhain A, Mackinnon M, Hunt P, Walliker D: High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcr and the multidrug resistance gene pfmdr1. J Infect Dis 2001, 183:1535–1538.

34. Backo LK, Lebras J, Rhoades Z, Wilson CM: Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from sub-Saharan Africa. Mol Biochem Parasitol 1995, 74:157–166.

35. Copean S, Noel A, Garnier D, Hubert V, Le BJ, Durand R: Lack of association between putative transporter gene polymorphisms in Plasmodium falciparum and chloroquine resistance in imported malaria isolates from Africa. Malar J 2006, 5:24.

36. Durasaisingh MT, Jones P, Samnou I, Von Seidlein L, Pinder M, Warhurst DC: The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 2000, 108:13–23.

37. Awad el-KFM, Miles MA, Warhurst DC: Chloroquine-resistant Plasmodium falciparum isolates from the Sudan lack two mutations in the pfmdr1 gene thought to be associated with chloroquine resistance. Trans R Soc Trop Med Hyg 1992, 86:587–589.

38. Backo LK, Ringwald P: Molecular epidemiology of malaria in Cameroon. X. Evaluation of pfmdr1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. Am J Trop Med Hyg 2002, 66:667–671.

39. Flueck TP, Jelinek T, Kilian AH, Adagu IS, Kabagambe G, Sonnenburg F, Warhurst DC: Correlation of in vivo-resistance to chloroquine and allelic polymorphisms in Plasmodium falciparum isolates from Uganda. Trop Med Int Health 2000, 5:174–178.

40. Grobusch MP, Adagu IS, Kremsner PG, Warhurst DC: Plasmodium falciparum: in vitro chloroquine susceptibility and allele-specific PCR detection of Pfmdr1 Asn86Tyr polymorphism in Lambarene, Gabon. Parasitology 1998, 116:211–217.

41. Habbal CP, Gbotoosh GO, Falarine OA, Bolaji OM, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AM: Association between mutations in Plasmodium falciparum chloroquine resistance transporter and Pf. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in Pf. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg 2006, 75:155–161.

42. Djimde AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Dama S, Ouolouguem D, Dicko A, Doumbo OK: Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg 2008, 78:455–461.

43. Holmgen G, Gil JP, Ferreira PM, Veiga MI, Obono CO, Bjorkman A: Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcr 76 T and pfmdr1 B67F. Infect Genet Evol 2006, 6:309–314.

44. Holmgen G, Hamrin J, Svad J, Martensson A, Gil JP, Bjorkman A: Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol 2007, 7:562–569.

45. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP: In vivo selection of Plasmodium falciparum Pfmdr1 B67F N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 2005, 191:1014–1017.